In this issue:
AtTEnd: atezolizumab + chemotherapy for advanced/recurrent endometrial cancer
Germline BRCA pathogenic variants in ovarian cancer & post-PARPi MDS/AMLs
Efficacy of chemotherapy after progression during/after PARPi in ovarian cancer
cfDNA molecular profiling in advanced endometrial cancer
GX-188E DNA vaccine + pembrolizumab in HPV 16/18-positive recurrent/advanced cervical cancer
Treatment outcomes of vulvar & vaginal melanomas
US uterine cancer trends
COUPLET: rucaparib + atezolizumab in advanced gynaecological cancers
ENSURE: patient satisfaction with reduced follow-up care for endometrial cancer
Intraperitoneal nivolumab after complete cytoreductive surgery & HIPEC in recurrent, advanced ovarian cancer
Please login below to download this issue (PDF)